Psoriasis (Pustulosis Palmaris et Plantaris)

A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

Also Known As:

Networked: 15577 relevant articles (2130 outcomes, 2617 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Psoriatic Arthritis
2.	Rheumatoid Arthritis
3.	Skin Diseases
4.	Atopic Dermatitis (Atopic Eczema)
5.	Crohn Disease (Crohn's Disease)

Experts

1.	Feldman, Steven R: 137 articles (12/2015 - 01/2002)
2.	Gottlieb, Alice B: 102 articles (08/2015 - 05/2002)
3.	Menter, Alan: 97 articles (10/2015 - 01/2002)
4.	Krueger, James G: 76 articles (11/2015 - 05/2002)
5.	van de Kerkhof, P C M: 70 articles (10/2015 - 03/2002)
6.	Chimenti, Sergio: 70 articles (10/2015 - 04/2005)
7.	Griffiths, C E M: 63 articles (04/2015 - 03/2002)
8.	Lebwohl, Mark: 60 articles (10/2015 - 05/2002)
9.	Koo, John: 55 articles (12/2015 - 05/2002)
10.	Krueger, Gerald G: 54 articles (12/2015 - 04/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Psoriasis:

1.	TNFR-Fc fusion protein (etanercept)FDA Link 02/01/2009 - "To assess the cost-effectiveness of etanercept 50 mg biw for the treatment of chronic plaque psoriasis, and to explore characteristics of patients who benefited most from 50 mg dosing. " 09/01/2011 - "Marked improvement in nail psoriasis during treatment with etanercept." 08/01/2010 - "In two previous phase 3 studies, up to 60 weeks of etanercept therapy significantly improved the symptoms of psoriasis and was well tolerated. " 06/01/2005 - "In previous studies, etanercept significantly improved plaque psoriasis and was well tolerated. " 05/01/2010 - "In conclusion, etanercept provided significant, sustained improvement in disease severity and was well tolerated in children > or = 8 years with severe plaque psoriasis."
2.	calcipotriene (calcipotriol)FDA LinkGeneric 07/01/2000 - "Given the greater safety and efficacy of combination regimens in terms of both short-term improvement and long-term control, initiating psoriasis treatment with a combination regimen of topical calcipotriene combined with an ultrapotent corticosteroid appears to be the most cost-effective approach to psoriasis treatment." 04/01/1994 - "At the end of the study period 60% of patients on calcipotriol showed clearance or marked improvement of their psoriasis compared with 17% on placebo. " 09/01/1996 - "Calcipotriol is effective in the treatment of psoriasis and it is an important addition to the therapeutic medications available to treat psoriasis. " 07/01/1994 - "Topical treatment of psoriasis with calcipotriol has been proven effective. " 01/01/2005 - "Topical Calcipotriol is an effective treatment for nail psoriasis and can be considered to be a safe topical treatment in chronic cases; its high tolerability allows prolonged usage without severe side effects."
3.	Cyclosporine (Ciclosporin)FDA LinkGeneric 09/20/1992 - "Several controlled clinical studies have shown that cyclosporin is highly effective in controlling severe psoriasis. " 06/01/2003 - "Cyclosporin is known to be highly effective in the treatment of psoriasis in adults. " 01/01/2001 - "Cyclosporine is highly effective and well tolerated in the short term treatment of severe psoriasis." 11/29/1997 - "New therapies aimed at reducing T cell activity are most successful, as exemplified by the efficacy of systemic cyclosporine in severe cases of psoriasis. " 06/01/1996 - "Cyclosporine has proved to be highly effective in the treatment of psoriasis. "
4.	infliximab (Remicade)FDA Link 03/01/2008 - "Based on four randomized, placebo-controlled, double-blind clinical trials and nine open-label uncontrolled trials of the use of infliximab in plaque psoriasis, it was found that infliximab is a highly efficacious, rapid, sustainable, and relatively safe therapy. " 02/01/2014 - "This suggests that while the management of psoriasis patients with comorbid conditions and various unfavorable prognostic characteristics requires a multidisciplinary approach to ensure the patient obtains the best therapeutic response, infliximab is an effective and well tolerated treatment in these patients." 01/01/2009 - "Infliximab appears to be the most effective treatment for nail psoriasis to date." 06/01/2003 - "Scientists noticed the marked skin improvement of this patient and later demonstrated the efficacy of infliximab for psoriasis in a randomized, double-blind, placebo-controlled trial. " 12/01/2011 - "Infliximab is very effective in the treatment of psoriasis either with nail involvement and/or PsA. "
5.	Methotrexate (Mexate)FDA LinkGeneric 05/01/2012 - "While methotrexate is the most frequently used systemic treatment for psoriasis, its efficacy for psoriasiform lesions related to anti-TNF therapy remains unknown. " 01/01/2009 - "Methotrexate is the best treatment for severe psoriasis. " 01/01/2006 - "Methotrexate appears to be the most cost-effective agent for the treatment of severe psoriasis. " 08/01/2007 - "Methotrexate is the gold standard therapy for moderate to severe psoriasis, but there is marked interpersonal variation in its efficacy and toxicity. " 10/01/2004 - "Methotrexate 0.25% in a hydrophilic gel is well tolerated but is not very effective in controlling the lesions of psoriasis on the palms and soles. "
6.	adalimumab (Humira)FDA Link 12/01/2014 - "Our data suggests that treatment with Adalimumab may promise best results in psoriasis-patients with (A) low baseline anti-dsDNA concentrations, and (B) no previous TNF-α antagonist treatment. " 11/01/2008 - "Adalimumab proved highly effective in psoriasis patients and in PsA patients previously unresponsive to nonsteroidal anti-inflammatory drugs. " 01/01/2009 - "The marked improvement of our two cases indicates that adalimumab may also help ameliorate nail psoriasis and warrants further controlled studies to establish the effectiveness and therapeutic regimes." 06/01/2015 - "Adalimumab has proven to be effective in suppressing psoriasis disease activity and is administered in a standard dose. " 11/01/2013 - "While adalimumab is a mainstay of treatment for moderate to severe chronic plaque psoriasis, the data regarding optimal treatment intervals for therapeutic maintenance are limited. "
7.	monoclonal antibody CNTO 1275 (CNTO 1275)FDA Link 09/30/2015 - "To the best of our knowledge, these are the first cases reported in the literature describing the long-term good efficacy of ustekinumab not only on paradoxical forms of psoriasis induced by anti-TNF-α drugs, but also on the articular involvement in a patient affected by RA and in a patient affected by Sjögren syndrome." 02/01/2014 - "Ustekinumab seems to be the most favorable biologic in term of cost per PASI 75 responder for the treatment of psoriasis and it is cost-effective in all scenarios analyzed. " 10/01/2011 - "Treatment with ustekinumab resulted in striking clearance of the psoriasis changes at the tattoo site." 05/17/2008 - "Although treatment with ustekinumab every 12 weeks is effective for most patients with moderate-to-severe psoriasis, intensification of dosing to once every 8 weeks with ustekinumab 90 mg might be necessary to elicit a full response in patients who only partially respond to the initial regimen." 05/17/2008 - "Ustekinumab seems to be efficacious for the treatment of moderate-to-severe psoriasis; dosing every 12 weeks maintains efficacy for at least a year in most patients."
8.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/01/2015 - "Tumor necrosis factor-alpha (TNF-α) antagonists have shown remarkable efficacy in psoriasis; however, the precise mechanisms of action of TNF-α blocking agents mainly focus on their neutralizing TNF-α and its anti-inflammatory effects. " 08/01/2015 - "Tumor necrosis factor (TNF)-blocking agents have proven to be highly efficacious in the management of moderate-to-severe psoriasis. " 05/01/2013 - "Biologics such as tumor necrosis factor (TNF) inhibitors are highly effective for treating severe psoriasis, and an increasing number of patients benefit from them. " 08/01/2012 - "Besides, tumor necrosis factor-α (TNF-α), a vital pro-inflammatory cytokine in psoriasis, in the supernatant of HaCat cells was dramatically reduced by GP-I. Collectively, these findings suggested that GP-I was a promising agent to be developed for psoriasis treatment in clinical therapy." 09/01/2009 - "All three of the TNFalpha antagonists have remarkable efficacy in patients with severe psoriasis. "
9.	efalizumabFDA Link 06/01/2009 - "Efalizumab is an effective and safe treatment for psoriasis in most patients of a high need population in routine practice, and provides maintained improvement in 'responders'. " 01/01/2009 - "The authors present a case of a patient with severe inverse psoriasis who was successfully treated with efalizumab, resulting in complete and sustained remission during prolonged maintenance therapy." 09/01/2005 - "Efalizumab thus appears as an important option in the long-term management of chronic plaque psoriasis." 01/01/2005 - "In randomized, double-blind, placebo-controlled trials, efalizumab 1.0 mg/kg, administered subcutaneously once weekly for 12 weeks, significantly reduced disease activity in patients with chronic, moderate-to-severe plaque psoriasis. " 01/01/2004 - "Compared to placebo-treated patients, efalizumab-treated patients showed significant improvement in patient-reported outcomes, reducing the limitations and burden associated with moderate to severe psoriasis within each of the three studies, as measured by DLQI (p<0.001), PSA-Severity (p<0.001), PSA-Frequency (p<0.001), and Itch (p<0.001) scores. "
10.	Anthralin (Dithranol)IBA 11/01/2015 - "Despite the known limitations of CID, this survey indicates that dithranol remains a highly efficacious and valuable treatment option as induction therapy in psoriasis. " 11/01/2015 - "Despite the known limitations of CID, this survey indicates that dithranol remains a highly efficacious and valuable treatment option as induction therapy in psoriasis. " 01/01/2001 - "Dithranol is highly effective in the treatment of psoriasis, however its mode of action is still not well known. " 01/01/2000 - "For UVB, the most effective wavelength in clearing psoriatic lesions was found to be of 313 nm. The efficacy of whole body exposure to narrow-band UVB (311 nm) combined with dithranol in psoriasis has not been evaluated to date. " 08/01/1998 - "Anthralin is the most common therapeutic agent among a small number of pro-oxidant, 9-anthrones effective in the topical treatment of psoriasis. "

Therapies and Procedures

1.	Phototherapy (Light Therapy) 01/01/2013 - "When combined with a systems biology approach, this potential biomarker may provide insight into which wavelengths of UV are the most effective in clearing psoriasis, allowing a more rational and potentially an individually tailored approach to optimising phototherapy for psoriasis." 03/01/2012 - "UVB is most commonly preferred as a first-line treatment for moderate to severe psoriasis in healthy adults, and preferences vary based on region, phototherapy availability, and prior treatment use." 05/01/2011 - "The purpose of this review is to provide some practical guidance to general dermatologists and residents on the specifics of using phototherapy, which, despite its decreasing use, remains one of our most safe and effective treatment strategies for psoriasis care. " 01/01/2010 - "Narrow-spectrum UVB phototherapy is considered highly effective in extensive psoriasis. " 01/01/2003 - "Narrowband UVB is highly effective for plaque psoriasis, but requires multiple phototherapy treatments, making patient compliance problematic. "
2.	Biological Therapy 07/01/2015 - "Biological therapies have dramatically improved the prognosis of Psoriasis. " 01/01/2015 - "Current biologic therapies are highly effective in the treatment of psoriasis, transforming the lives of patients with this significantly disabling disease. " 10/01/2010 - "Total healthcare costs associated with treatment of severe psoriasis with biologic therapy are significantly greater than with traditional systemic therapy. " 01/01/2008 - "With the coming of the biological therapies, long-term maintained control of psoriasis is becoming a reality and means a significant improvement in the quality of life in some patients with persistent clearing of the disease. " 06/01/2013 - "In this study, more patients receiving biologic therapies improved from severe to moderate or mild psoriasis than patients on other treatments. "
3.	Photochemotherapy (Photodynamic Therapy) 04/01/2015 - "After comparing the anti-psoriasis effects of saline, light alone, ZPB alone, and the combination of light and ZPB, the combination of light and ZPB showed the best photodynamic therapy of psoriasis based on the light excitation of the photosensitizer ZPB and the psoriasis was nearly cured according to the histopathological investigation. " 12/01/1992 - "Photochemotherapy is effective treatment for photosensitive psoriasis." 02/01/2000 - "Systemic photodynamic therapy is a safe and effective treatment for psoriasis." 04/01/1991 - "Relative efficacy of 335 and 365 nm radiation in photochemotherapy of psoriasis." 06/01/2003 - "Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy."
4.	Aftercare (After-Treatment) 08/01/1996 - "Forty-two percent were still clear 1 year after treatment and there was no significant difference in the number of days in remission between the regimens for those whose psoriasis had recurred. " 08/01/1996 - "There was significant improvement in Psoriasis Disability Index, which was derived from a questionnaire assessing functional disability and completed by the patients before and after treatment. " 08/01/1992 - "Rapid clinical improvement, with major reduction of the Psoriasis Area Severity Index, was observed during 1 month after treatment. " 01/01/1992 - "However, when the levels of SC5b-9 in the psoriatic plasma were compared before and after successful treatment of psoriasis, a significant reduction was observed after treatment. " 06/01/2005 - "Evaluation of therapeutic efficacy was performed by comparing their Psoriasis Area and Severity Index (PASI) scores before and after treatment. "
5.	Excimer Lasers 12/01/2013 - "Excimer laser treatment is highly effective in psoriasis, another T cell-mediated disorder that shares many immunologic features with AA. " 07/01/2013 - "The 308-nm excimer laser is an effective, safe, easy, and relatively quicker method for the treatment of psoriasis at difficult to treat sites, with good results in a somewhat short time. " 10/01/2010 - "The 308-nm excimer laser is an effective and safe modality for the treatment of psoriasis, with good results achieved in a relatively short time." 11/01/2007 - "Excimer laser treatment for psoriasis has been associated with good results at a lower cumulative dose than narrowband ultraviolet (UV)B protocols. " 05/01/2002 - "As little as one high-dose excimer laser treatment can be effective for localized plaque-type psoriasis. "